Medicines for the People Act

This bill, titled the Medicines for the People Act, would create a new National Institute for Biomedical Research and Development within the Public Health Service Act. The new institute would conduct full-cycle research and development of drugs, devices, and biological products using federal laboratories, contracts with public and private entities, and acquisitions of existing technologies. Key provisions include government ownership of patents and trade secrets from institute-funded research, mandatory sharing of clinical trial data with the public, and licensing agreements that prioritize nonprofit and public entities while allowing some for-profit licensing under public interest terms. The institute would be overseen by a 15-member governing board with restrictions on members from the pharmaceutical industry, and it would receive an initial authorization of $90 billion for fiscal year 2027.